Benjamin A. Fisher

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial.

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Rheumatology

Published: November 11, 2025

Immune checkpoint inhibitor-induced inflammatory arthritis.

Immune checkpoint inhibitor-induced inflammatory arthritis.

Journal: Clinical medicine (London, England)

Published: April 14, 2025

Concomitant Sjögren's disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort.

Concomitant Sjögren's disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort.

Journal: Arthritis research & therapy

Published: September 17, 2023

Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases.

Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases.

Journal: Med (New York, N.Y.)

Published: March 23, 2022

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.

Journal: Critical reviews in immunology

Published: January 01, 2022

Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.

Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.

Journal: Alimentary pharmacology & therapeutics

Published: April 15, 2020

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Journal: Trials

Published: December 05, 2018

High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis.

High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis.

Journal: Rheumatology (Oxford, England)

Published: August 15, 2018

The RA-MAP Consortium: a working model for academia-industry collaboration.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Journal: Nature reviews. Rheumatology

Published: December 08, 2017

High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control study.

High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control study.

Journal: Annals of the rheumatic diseases

Published: August 23, 2017

Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro.

Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro.

Journal: The Journal of rheumatology

Published: December 21, 2016

Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis.

Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis.

Journal: Clinical and experimental rheumatology

Published: February 15, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026